Abstract
The first successful transcatheter closure of an ASD was performed by King and Mills in 1974. The device was composed of two opposing umbrellas and required a 23 Fr introducer. Since then different device designs have been studied. There are now two FDA-approved devices used for ASD closure: AMPLATZER Septal Occluder® and Helex®. Secundum atrial septal defects are usually closed to reduce right ventricular volume overload (RVVO) which is diagnosed by echo or MRI. In the presence of RVVO by noninvasive measures the ASD meets indication for closure, even when the measured Qp/Qs in the lab may suggest a less than 2:1 shunt. However, occasional patients get to the lab with a misdiagnosis or missed diagnosis, e.g., the TEE shows intact septum, multiple defects, or there are pulmonary venous anomalies, which may make ASD closure inappropriate.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAuthor information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Bergersen, L., Foerster, S., Marshall, A.C., Meadows, J. (2009). ASD Device Closure. In: Bergersen, L., Foerster, S., Marshall, A.C., Meadows, J. (eds) Congenital Heart Disease. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-77292-9_17
Download citation
DOI: https://doi.org/10.1007/978-0-387-77292-9_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-77291-2
Online ISBN: 978-0-387-77292-9
eBook Packages: MedicineMedicine (R0)